Correction: Antibiotics in the clinical pipeline as of December 2022

Affiliations

¹ Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. m.butler5@uq.edu.au.
² Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
³ Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. m.blaskovich@uq.edu.au.

Published Erratum

Mark S Butler et al. J Antibiot (Tokyo). 2024 Jan.

. 2024 Jan;77(1):71.

doi: 10.1038/s41429-023-00671-6.

¹ Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. m.butler5@uq.edu.au.
² Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
³ Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia. m.blaskovich@uq.edu.au.

No abstract available

Erratum for

Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. Butler MS, et al. J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8. J Antibiot (Tokyo). 2023. PMID: 37291465 Free PMC article. Review.